| Literature DB >> 33889387 |
Melisa A Muñoz-Ruiz1, Laura I González-Zapata1,2, Victoria Abril-Ulloa3,4, Diego A Gaitán-Charry1.
Abstract
The present study aimed to assess the associations of the stages of Fe deficiency (Fe deficiency without anaemia (ID) and Fe-deficiency anaemia (IDA)) and anaemia with metabolic syndrome (MetS) in Ecuadorian women. A cross-sectional study was conducted in 5894 women aged 20-59 years, based on data from the 2012 Ecuadorian National Health and Nutrition Survey. The sample was stratified by age. A χ 2 test was used to assess the possible associations of ID, IDA and anaemia with MetS. The prevalence ratio (PR) for each stage of Fe deficiency and anaemia was estimated considering women without MetS as a reference. The total prevalence of MetS, ID, IDA and anaemia was 32⋅3 % (se 0⋅6), 6⋅2 % (se 0⋅3), 7⋅1 % (se 0⋅3) and 5⋅0 % (se 0⋅3), respectively. In women aged 20-29, 30-39 and 40-49 years, MetS was associated with a lower prevalence of ID (PR (95 % CI; P-value)): 0⋅17 (0⋅06, 0⋅46; P < 0⋅001), 0⋅69 (0⋅48, 0⋅99; P = 0⋅044) and 0⋅44 (0⋅29, 0⋅67; P < 0⋅001), respectively. In women aged 50-59 years, MetS was associated with IDA and anaemia (PR (95 % CI; P-value)): 0⋅12 (0⋅02, 0⋅96; P = 0⋅026) and 0⋅22 (0⋅07, 0⋅64; P = 0⋅002), respectively. In conclusion, Ecuadorian women of reproductive age with MetS have a lower prevalence of ID compared with those without MetS. Furthermore, the MetS and IDA coexist at the population level. These findings require an analysis from a dietary pattern approach, which could provide key elements for developing public policies that simultaneously address all forms of malnutrition.Entities:
Keywords: Iron deficiency; Iron-deficiency anaemia; Metabolic syndrome; Women
Mesh:
Year: 2021 PMID: 33889387 PMCID: PMC8057425 DOI: 10.1017/jns.2020.55
Source DB: PubMed Journal: J Nutr Sci ISSN: 2048-6790
Socio-demographic characteristics of participants: Ecuadorian women aged 20–59 years (data from the ENSANUT-ECU 2012)
| % | ||
|---|---|---|
| Age (years) | ||
| 20–29 | 1752 | 29⋅7 |
| 30–39 | 2102 | 35⋅7 |
| 40–49 | 1642 | 27⋅9 |
| 50–59 | 398 | 6⋅8 |
| Ethnicity | ||
| Indigenous | 569 | 9⋅7 |
| Afro-Ecuadorian | 203 | 3⋅4 |
| Montubio | 173 | 2⋅9 |
| Mestizo, white and others | 4949 | 84⋅0 |
| Economic status index | ||
| Q1 (poorest) | 1300 | 22⋅1 |
| Q2 | 1339 | 22⋅7 |
| Q3 | 1173 | 19⋅9 |
| Q4 | 1091 | 18⋅5 |
| Q5 (wealthiest) | 988 | 16⋅8 |
| BMI category | ||
| Thinness | 72 | 1⋅2 |
| Normal | 1856 | 31⋅5 |
| Overweight | 2441 | 41⋅4 |
| Obesity | 1525 | 25⋅9 |
BMI categories were defined according to WHO: thinness (BMI < 18⋅5 kg/m2), normal (BMI ≥ 18⋅5–24⋅9 kg/m2), overweight (BMI ≥ 25–29⋅9 kg/m2) and obesity (BMI ≥ 30 kg/m2).
Total = 5894.
Women with no data n = 3.
Anthropometrical, biochemical and clinical biomarkers of participants: Ecuadorian women aged 20–59 years (data from the ENSANUT-ECU 2012)
| Mean | Minimum | Maximum | ||
|---|---|---|---|---|
| Height (cm) | 151⋅9 | 6⋅1 | 99⋅9 | 198⋅3 |
| Weight (kg) | 63⋅2 | 11⋅8 | 33⋅0 | 138⋅7 |
| BMI (kg/m2) | 27⋅3 | 4⋅7 | 15⋅0 | 52⋅7 |
| Median | IQR | p5 | p95 | |
| Haemoglobin (g/dl) | 13⋅2 | 1⋅3 | 11⋅1 | 14⋅6 |
| Serum ferritin (μg/l) | 44⋅0 | 52⋅0 | 7⋅0 | 169⋅3 |
| CRP (mg/l) | 1⋅9 | 1⋅5 | 1⋅9 | 7⋅0 |
| Fasting glucose (mg/dl) | 88⋅0 | 13⋅0 | 72⋅0 | 109⋅0 |
| HDL (mg/dl) | 44⋅0 | 15⋅0 | 28⋅0 | 67⋅0 |
| TAG (mg/dl) | 107⋅0 | 80⋅0 | 48⋅0 | 274⋅0 |
| WC (cm) | 87⋅2 | 14⋅4 | 71⋅2 | 106⋅7 |
| SBP (mmHg) | 113⋅0 | 15⋅5 | 96⋅0 | 138⋅0 |
| DBP (mmHg) | 70⋅5 | 12⋅5 | 58⋅0 | 88⋅0 |
sd, standard deviation; IQR, interquartile range; CRP, C-reactive protein; WC, waist circumference, SBP, systolic blood pressure; DBP, diastolic blood pressure.
For all variables, the significance of the Kolmogorov–Smirnov test was P < 0⋅01.
Prevalence of the stages of iron deficiency and anaemia according to metabolic syndrome diagnosis in Ecuadorian women aged 20–59 years (data from the ENSANUT-ECU 2012)
| Deficiency category | Metabolic syndrome | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Total | |||||||
| % | % | % | |||||||
| No deficit | 1639 | 27⋅8 | 0⋅6 | 3174 | 53⋅9 | 0⋅6 | 4813 | 81⋅7 | 0⋅5 |
| ID | 69 | 1⋅2 | 0⋅1 | 299 | 5⋅1 | 0⋅3 | 368 | 6⋅2 | 0⋅3 |
| IDA | 118 | 2⋅0 | 0⋅2 | 300 | 5⋅1 | 0⋅3 | 418 | 7⋅1 | 0⋅3 |
| Anaemia | 79 | 1⋅3 | 0⋅1 | 216 | 3⋅7 | 0⋅2 | 295 | 5⋅0 | 0⋅3 |
| Total | 1905 | 32⋅3 | 0⋅6 | 3989 | 67⋅7 | 0⋅6 | 5894 | 100⋅00 | |
se, standard error; ID, Fe deficiency; IDA, Fe-deficiency anaemia.
ID was defined as serum ferritin <15 μg/l as proposed by WHO(.
Anaemia was defined as Hb <12 g/dl after adjustment by altitude as proposed by WHO(.
IDA was defined as the presence of serum ferritin <15 μg/l and anaemia(.
MetS definition was based on the harmonised definition (2009), with at least three of the following criteria: waist circumference ≥ 80 cm; fasting glucose ≥ 100 mg/dl; TAG ≥ 150 mg/dl; HDL < 50 mg/dl; systolic blood pressure ≥ 130 and/or diastolic blood pressure ≥ 85 mmHg or antihypertensive drug treatment in a patient with a history of hypertension(.
Association of metabolic syndrome with the stages of iron deficiency and anaemia by age, in Ecuadorian women aged 20–59 years (data from the ENSANUT-ECU 2012)
| Age | MetS | ID | IDA | Anaemia | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PR | 95 % CI | PR | 95 % CI | PR | 95 % CI | |||||
| 20–29 years ( | No | 1⋅00 | Ref | – | 1⋅00 | Ref | – | 1⋅00 | Ref | – |
| Yes | 0⋅17 | 0⋅06, 0⋅46 | 0⋅000 | 0⋅57 | 0⋅31, 1⋅06 | 0⋅067 | 0⋅66 | 0⋅36, 1⋅23 | 0⋅185 | |
| 30–39 years ( | No | 1⋅00 | Ref | – | 1⋅00 | Ref | – | 1⋅00 | Ref | – |
| Yes | 0⋅69 | 0⋅48, 0⋅99 | 0⋅044 | 0⋅85 | 0⋅61, 1⋅19 | 0⋅333 | 0⋅82 | 0⋅53, 1⋅28 | 0⋅389 | |
| 40–49 years ( | No | 1⋅00 | Ref | – | 1⋅00 | Ref | – | 1⋅00 | Ref | – |
| Yes | 0⋅44 | 0⋅29, 0⋅67 | 0⋅000 | 0⋅74 | 0⋅55, 1⋅01 | 0⋅055 | 0⋅74 | 0⋅50, 1⋅10 | 0⋅138 | |
| 50–59 years ( | No | 1⋅00 | Ref | – | 1⋅00 | Ref | – | 1⋅00 | Ref | – |
| Yes | 0⋅54 | 0⋅09, 3⋅21 | 0⋅660 | 0⋅12 | 0⋅02, 0⋅96 | 0⋅026 | 0⋅22 | 0⋅07, 0⋅64 | 0⋅002 | |
MetS, metabolic syndrome; ID, Fe deficiency; IDA, Fe-deficiency anaemia; PR, crude prevalence ratio; Ref, reference category; 95 % CI, 95% confidence interval.
Two-tailed P-values for Fisher's exact test, and the remaining two-tailed P-values were assessed by χ2 test.